Esophagus · 2022 · 17 citations · 27 references
MedicineOncologyChemotherapyOncologic SurgerySurgical OncologyChemotherapy Toxicity ManagementEsophageal CancerMalignant NeoplasmsPalliative ChemotherapyToxicity Management5-Fluorouracil TreatmentChemotherapy Dose IntensityHistopathological ResponseOxaliplatin-based TherapyPreoperative ChemotherapyR0 ResectionRelative Dose IntensityShort-term Efficacy Evaluation
BACKGROUND: The standard preoperative treatment for resectable locally advanced esophageal squamous cell carcinoma (LAESCC) in Japan is docetaxel, cisplatin (CDDP), and 5-fluorouracil. However, patients with renal or cardiac dysfunction and elderly patients are ineligible for a CDDP-containing regimen because of toxicities. Oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX) therapy has less renal toxicity than CDDP-containing regimens and does not require hydration. However, there are limited data on preoperative FOLFOX therapy in these patients. METHODS: This retrospective study analyzed patients with resectable LAESCC who were aged ≥ 75 years or had renal or cardiac dysfunction and received preoperative FOLFOX between 2019 and 2021. FOLFOX was administered every 2 weeks for 3 or 4 cycles and was followed by surgery. Adverse events associated with chemotherapy, the complete resection (R0) rate, relative dose intensity (RDI), and histopathological response were evaluated. RESULTS: Thirty-five patients were eligible. Median age was 77 (range 65-89) years; 68.6% were aged ≥ 75 years, 74.3% had renal dysfunction, and 17.1% had cardiac dysfunction. The RDI was 70.2% and 87.1% for bolus and continuous intravenous 5-fluorouracil, respectively and 85.2% for oxaliplatin. The most common grade ≥ 3 adverse events were neutropenia (60.0%) and leucopenia (28.6%). Two patients (5.7%) had febrile neutropenia and grade 3 pneumonia. Thirty-one patients underwent surgery. The R0 resection rate was 87.1%, and there was no histopathological evidence of residual tumor in 16.1%. There were no treatment-related deaths. CONCLUSIONS: Preoperative FOLFOX had a manageable safety profile and showed favorable short-term efficacy in patients with resectable LAESCC who were ineligible for CDDP-containing treatment.
27
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
Ronan J. Kelly, Jaffer A. Ajani, Thomas Zander et al. · New England Journal of Medicine · 2021 · 1.8K citations · Full text
Nobutoshi Ando, Hoichi Kato, Hiroyasu Igaki et al. · Annals of Surgical Oncology · 2011 · 1.4K citations